The prevalence of heart failure (HF) has been steadily increasing and it now creates an enormous social and economic burden. HF is a syndrome characterized by a high mortality rate, frequent hospitalization, a reduced quality of life, and a complex therapeutic regimen. In the last three decades, major progress in both the diagnosis and management of HF has taken place, and the pharmacologic and non-pharmacologic advances have led to a significant improvement in survival and symptoms in HF patients. After an accurate diagnosis, a proper HF management plan requires a multi-level team approach comprised of the correct combination of drug therapy, device therapy, and surgery, including heart transplantation. In this review, we focused on the pharmacologic and non-pharmacologic treatment strategies for HF with reduced ejection fraction. The goal was to develop treatment guidelines based on significant evidence derived from large clinical trials. ( 
HFrEF, heart failure with reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; LV, left ventricular. HF, heart failure; HTN, hypertension; DM, diabetes mellitus; MI, myocardial infarction; LV, left ventricular; LVH, left ventricular hypertrophy; EF, ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; GDMT, guideline-directed medical therapy; ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin-receptor blocker; ICD, implantable cardioverter-defibrillator; HRQOL, health-related quality of life; AF, atrial fibrillation; CAD, coronary artery disease; CRT, cardiac resynchronization therapy; MCS, mechanical circulatory support. European Medicines Agency has approved ivabradine for use in patients with a heart rate ≥ 75 b.p.m. May also be considered in patients with a contraindication to a beta-blocker or beta-blocker intolerance. f Indication differs according to heart rhythm, NYHA class, QRS duration, QRS morphology and LVEF. g Not indicated in NYHA class IV. h Digoxin may be used earlier to control the ventricular rate in patients with atrial fibrillation-usually in conjunction with a beta-blocker. i The combination of hydralazine and isosorbide dinitrate may also be considered earlier in patients unable to tolerate an ACE inhibitor or an ARB. Table 4) .
최근 새로운 알도스테론 길항제인 eplerenone은 EPHESUS
연구에서 심근경색 14일 이내인 좌심실 박출률 ≤ 40% 환자 에서 1년 내 사망률을 13.6%에서 11.8%로 감소시켰다 [22] .
Eplerenone은 아직 우리나라에서 사용할 수 없다. 중심 단어: 수축기 심부전; 진료 지침
